Resumen de: US2023094433A1

Methods, kits, and oligonucleotides used in the detection of the coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The oligonucleotide consists of 40 or less nucleotides and has a nucleotide sequence that consists essentially of, or is a variant of, the nucleotide sequence of: SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

Resumen de: US2023094263A1

Provided herein are methods for treating coronavirus diseases. In one embodiment, the method comprises administering to a coronavirus disease patient a therapeutic amount of decidua stromal cells. In one embodiment, the method comprises administering to the subject a therapeutic amount of decidua stromal cells (DSCs). In some embodiments, the coronavirus disease is SARS, MERS or COVID-19. The method of the disclosure can be used to treat a subject who has acute respiratory distress syndrome (ARDS), acute lung injury (ALI), or both.

Resumen de: US2023101514A1

The present invention provides a platform providing curated entertainment options and event suggestions based on preference data associated with a user profile and/or feedback provided regarding the entertainment options and event suggestions. The platform is configured to receive feedback regarding pandemic compliance measures (e.g., COVID-19 safety protocols) and/or disability accommodations provided by the one or more venues and/or events. The platform includes an artificial intelligence module, which analyzes the feedback regarding pandemic compliance measures and/or disability accommodations in order to generate custom-catered suggestions for each user profile.

Resumen de: AU2021342844A1

Disclosed herein is a composition which may be formulated as an aqueous antimicrobial formulation, in particular as an antimicrobial sanitizer formulation, or as an aqueous antimicrobial formulation which may be applied to a surface or an article. The formulation comprises up to about 5% w/v of a quaternary ammonium compound such as benzalkonium chloride, up 20% w/v of a nutrient carrier composition comprising Leptospermum petersonii (Lemon Bush) leaf extract, and optionally Matricaria chamomillia (Chamomile) flower extract, and up to about 99% w/v water. Also disclosed herein are applications for said compositions, which may be formulated without the need for an alcohol, and may be applied topically to a subject or article. The compositions may be beneficial to users while being effective against microbes including bacteria and viruses, such as COVID-19.

Resumen de: WO2023046900A1

The invention relates to nucleoside derivatives of formula (I), wherein R has the same meaning as that defined in the claims and the description. The present invention also relates to pharmaceutical compositions comprising such compounds and to uses of such compounds and compositions for the treatment or prevention of viral infections, more in particular infections caused by RNA virus, such as coronavirus infections.

Resumen de: EP4154887A1

This invention relates to a novel method for treating RNA viral infections including COVID-19 (SARS-CoV-2).A method for treating RNA viral infections, including COVID-19 (SARS-CoV-2), which consists in administering to the patient a pharmaceutical composition in the form of a tablet, capsule, pill, or powder containing Favipiravir as the active ingredient at a dose of ≥40 mg/kg/day on day 1 and at a dose of ≥16 mg/kg/day on subsequent days until the virus leaves the body, optionally in combination with concomitant medications.

Resumen de: WO2021236288A2

Disclosed herein are systems, methods, and techniques for building and using a data platform to facilitate intelligent identification of coronavirus disease 2019 (COVID-19) related diagnoses, treatment selection, and interaction tracing. The present disclosure relates to a cloud-based application that generates outputs predictive of a subject's COVID-19 diagnoses and/or suitability for COVID-19 treatments.

Resumen de: EP3912623A1

The present invention relates to MEK inhibitors for use in a method for the treatment of a coronavirus infection and/or the treatment or prevention of COVID-19 cytokine storm. Also provided are compositions comprising such inhibitors for use in the treatment of a corona virus infection, such as COVID-19.

Resumen de: WO2021237057A1

A liquid biopsy system and method for the detection of SARS-CoV-2 antibodies in bodily fluids is described. In particular, the system is suitable for detecting SARS-CoV-2 antibodies in a saliva sample of a subject.

Resumen de: EP4154878A1

Disclosed is an application of an active ingredient of Root of Ligulilobe Sage or a pharmaceutically acceptable salt thereof in preparing an antiviral drug. The application of the active ingredient of Root of Ligulilobe Sage or the pharmaceutically acceptable salt thereof in preparing an anti-SARS-Cov-2 drug is proposed for the first time, and a novel treatment means for a novel coronavirus infected person having a chronic underlying disease is provided; the application expands the use range of the active ingredient of Root of Ligulilobe Sage, and especially provides a novel drug for treating pneumonia (COVID-19) caused by novel coronavirus infection in the case of the global SARS-CoV-2 epidemic.

Resumen de: WO2021236532A1

The invention relates generally to viral infections and more specifically to compositions and methods for treating infections by SARS-CoV-2 (2019-nCoV). In particular, the invention provides a PNA agent which includes a PNA moiety with a sequence that targets a SARS-CoV-2 gene; a first cationic and hydrophobic peptide at the N-terminus of the PNA moiety, wherein the first peptide comprises lysine residues, and at least one of the lysine residues comprises a palmitoyl side chain moiety; and a second cationic and hydrophobic peptide at the C-terminus of the PNA moiety, wherein the second peptide comprises lysine residues, and at least one of the lysine residues comprises a palmitoyl side chain moiety.

Resumen de: EP4155406A1

Provided are an mRNA or an mRNA composition, and an mRNA vaccine comprising the mRNA or the mRNA composition. The mRNA or the mRNA composition comprises an mRNA sequence encoding an S protein of a novel coronavirus SARS-CoV-2 or a variant thereof, and an mRNA sequence encoding an RBD in the S protein or a variant thereof. Further provided are the applications of the mRNA or the mRNA composition, and the mRNA vaccine comprising the mRNA or the mRNA composition in preparation of a medication for preventing and/or treating a disease caused by a novel coronavirus SARS-CoV-2 infection.

Resumen de: EP4154884A1

The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I):[wherein R<1> is C1-C8 alkyl or the like; and R<2>-R<9> is hydrogen, halogen, hydroxyl, or Q-(Ci-Cs alkyl), (Q is O, NH, or S) or the like.], or a pharmaceutically acceptable salt thereof.

Resumen de: WO2021236509A1

Disclosed herein are anti-SARS-CoV-2 spike protein antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such antibodies.

Resumen de: WO2021236996A2

The subject matter described herein relates to potent monoclonal and bispecific antibodies capable of neutralizing a SARS-CoV-2 viruses and methods of generating the antibodies.

Resumen de: WO2021234392A1

There is provided inter alia a polypeptide comprising a CDRH1 sequence comprising or consisting of a sequence sharing 80% or greater sequence identity with a CDRH1 sequence as shown in Table 1 and/or a CDRH2 sequence comprising or consisting of a sequence sharing 80% or greater sequence identity with a CDRH2 sequence as shown in Table 1 and/or a CDRH3 sequence comprising or consisting of a sequence sharing 80% or greater sequence identity with a CDRH3 sequence as shown in Table 1.

Resumen de: WO2021236640A1

A novel assay which can differentiate a neutralizing antibody from non-neutralizing antibody which can be easily visualized, for example, by a portable UV lamp, among other visualization techniques. This assay can produce results in about 30 minutes and can be performed by untrained individuals in a non-laboratory environment. Also described is an ELISA method for determining if a human possesses at least one type of neutralizing antibody against SARS-Cov-2.

Resumen de: WO2021236854A1

Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

Resumen de: WO2021236134A1

The present disclosure provides methods of treating COVID-19 by administering a pharmaceutical composition providing inhibition of severe acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) main protease (MPro) in a patient. The disclosure also provides other methods as well as pharmaceutical formulations for use in treating COVID-19 patients.

Resumen de: WO2021233834A1

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.

Resumen de: WO2021233927A1

The present invention relates to an antibody that binds specifically to the SARS CoV-2 spike protein, and methods for its manufacture.

Resumen de: EP3913369A1

Field of inventionThe invention relates to an inactivation method of an inactivated SARS-CoV-2 virus, to be used in the preparation of immunological assays for the detection of antibodies in samples.

Resumen de: WO2021236415A1

Embodiments of the invention include immunogenic compositions that comprise an attenuated recombinant Francisella tularensis subspecies holarctica Live Vaccine Strain (LVS) having a deletion in a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens present on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Embodiments of the invention also include methods of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant Live Vaccine Strain lacking a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens expressed by a severe acute respiratory syndrome coronavirus 2 (SAR8- CoV-2) polypeptide.

Resumen de: CA3154812A1

The present disclosure provides a method for an effective decoction preparation of unripe green Mangifera indica to treat and prevent anti-SARS-CoV-2. The disclosure extends to uses of such preparation as medicaments and to methods of treating anti-SARS-CoV-2 infections, and tolerating the vaccine side-effects. The disclosure further extends to methods for preventing anti-SARS-CoV-2 infections by coating objects and surfaces with the compositions.

Resumen de: WO2023041985A2

The invention provides nanobodies that bind with high affinity to SARS-CoV- 2 non-structural protein (Nsp), as well and compositions comprising the identified nanobodies and methods of use thereof to block activation of SARS-CoV-2 viral replication, and for the treatment or prevention of COVID-19.